atai Life to merge with Beckley Psytech in a $390m deal.

atai Life, a clinical-stage biopharmaceutical company, agreed to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company, in a $390m deal. “The strategic combination marks a transformational moment, solidifying us as a leader in rapid-acting and accessible psychedelic treatments for mental health conditions with a pipeline of potential first-in-class and best-in-class assets. With a unified vision and a synergistic pipeline, we believe we are well-positioned to unlock the strategic value of our clinical development programs for both patients and shareholders. Together, we plan to move confidently towards our goal of bringing innovative interventional psychiatry therapies to patients in need of new treatments,” Srinivas Rao, atai CEO and Co-Founder.